. 2017 Dec 14;314(4):L529–L543. doi: 10.1152/ajplung.00465.2017

Table 3.

Summary of clinical trials: combination therapies

						Measure, Test, and Assay
Study Name	Treatment	Trial Phase No.	Mutations	Age Group, yr	Sample Size	ppFEV₁	BMI	CFQ-R	SwCl	Conclusion (Failed or Approved)	References
TRAFFIC/TRANSPORT (pooled results)	LUM 600 mg qd + IVA 250 mg q12 h	3	Homozygous F508de1	≥12	368	+3.3% (P < 0.001) [24]	+0.28 kg/m² (P < 0.001) [24]	+3.1 points (P = 0.007) [24]		Approved	^**
TRAFFIC/TRANSPORT (pooled results)	LUM 400 mg qd + IVA 250 mg q12 h	3	Homozygous F508de1	≥12	369	+2.8% (P < 0.001) [24]	+0.24 kg/m² (P < 0.001) [24]	+2.2 points (P = 0.05) [24]
EVOLVE	TEZ 100 mg qd + IVA 150 mg q12 h	3	Homozygous F508de1	≥12	248	+4.0% (P < 0.0001) [24]	+0.06 kg/m² (P = 0.4127) [24]	+5.1 points (P < 0.001) [24]			(57, 58)
EXPAND	TEZ 100 mg qd + IVA 150 mg q12 h	3	Homozygous F508de1	≥12	161	+6.8% (P < 0.0001) [8]		+11.1 points (P < 0.0001) [8]

^**